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icrovascular Obstruction
he Final Frontier for
Complete Myocardial Reperfusion*
arlos E. Rochitte, MD, PHD
ão Paulo, Brazil
icrovascular obstruction (MO), or no-reflow phenome-
on, defines an area within an acute myocardial infarction
MI) that had undergone not only myocyte necrosis but also
evere and irreversible microcirculation damage (1). It has
een shown that the presence of MO in humans after MI is
ssociated with poorer prognosis and worse left ventricle
LV) remodeling (2).
Since the description of the no-reflow phenomenon in
he myocardium by Kloner et al. (3) in 1974 as the absence
f blood flow restoration to the myocardium after a tempo-
ary coronary occlusion, research in this field has progressed
n 2 distinct directions.
See page 2230
One direction was the no-reflow definition in interven-
ional cardiology based on angiographic aspects (4), which
ccurred with the advent of thrombolysis and primary
ercutaneous coronary angioplasty and the observation of
low antegrade contrast filling in the infarct-related artery.
No-reflow definitions used Thrombolysis In Myocardial
nfarction (TIMI) flow score, TIMI frame count (5), and,
nally, intracoronary Doppler ultrasound with a typical
oppler pattern of angiographic no-reflow being a reduced
r absent antegrade systolic flow followed by a retrograde
ystolic flow and rapid deceleration of diastolic flow (6).
rognostic information and effect of drugs on MO was
erived from these measurements in several animal and
linical studies (7,8).
The other direction was the visualization of MO within
he myocardium by contrast echocardiography (9), nuclear
edicine (10), and cardiovascular magnetic resonance
CMR) (1–3,11,12). In both lines of studies, the term
no-reflow” was applied, referring to either angiographic
o-reflow or MO, generating some confusion but reflecting
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.c
From the Heart Institute (InCor), University of São Paulo Medical School, São
aulo, Brazil.distinct facets of the same pathophysiology, which is the
bstruction of microcirculation (3). Here, CMR took the
ead owing to its higher spatial resolution, signal-to-noise,
nd contrast-to-noise ratio compared with the other mo-
alities. In 1995, Lima et al. (12) were the first to detect
reas of hypoenhanced myocardium by CMR in humans.
nimal experiments by Judd et al. (11) and Rochitte et al.
1) confirmed the results and established a close correlation
etween hypoenhanced myocardial areas and blood flow at
he microcirculation level by microspheres.
In this issue of the Journal, a convergence of these 2
actions of investigation happened with Hirsch et al. (13).
he authors elegantly compared epicardial coronary blood
ow characteristics by intracoronary Doppler with MO
etected by CMR, the best techniques for angiographic and
issue no-reflow evaluation, respectively. Their data con-
rmed previous data from contrast-enhanced echocardiog-
aphy (9) and demonstrated that the magnitude of MO by
MR was the independent force driving the behavior of
oronary blood flow at the epicardial level. Despite investi-
ating only patients with first anterior MI, this study
rovides a great step forward in MO pathophysiology in
umans and in the definition of the best methodology to
urther this investigational field.
Cardiac magnetic resonance is very efficient for MO
etection and more sensitive than the best invasive method
f intracoronary Doppler. In the Hirsch et al. (13) study, all
atients with early systolic retrograde flow (SRF) had MO
y CMR, whereas none without SRF had MO. On the
ther side, only about one-half of patients with MO had
RF. The SRF may be detectable only in patients with a
reater extent and severity of MO.
However, for the quantification of MO there is one
ritical point in using CMR with gadolinium contrasts.
adolinium-based contrasts have an extracellular distribu-
ion in the myocardium and rapidly diffuse into the normal
nterstitial space as well as into areas of MO at a variable
ate, thus changing its size over time after injection.
In the Hirsch et al. (13) study, late gadolinium enhance-
ent (LGE) was performed 12 to 15 min after injection and
ight have underestimated the true extent and size of MO.
arlier studies using gradient-echo sequences (1), have
nvestigated the time course of MO and demonstrated in
anine models that at 3 min after contrast the area of MO
orrelated better with the size of the region with myocardial
lood flow 50% than remote regions by radioactive
icrospheres (1,11,14). This might explain why the extent
number of segments) had a more powerful correlation than
O size itself, which was probably underestimated. None-
heless, the time after gadolinium injection that best corre-
ates with true size of MO in humans still remains to be
etermined, particularly with the additional role of throm-
us and atherosclerotic material embolization present in the
linical situation of thrombolysis or PCI.
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Editorial Comment June 10, 2008:2239–40Another important aspect must be highlighted; MO is an
xtremely dynamic phenomenon, increasing progressively in
he first 48 h after reperfused acute MI (1), as described by
MR and basic studies (1,14,15). Thus, choosing the time
fter reperfusion is also crucial to investigate the magnitude
f MO.
Currently there is no consensus on which technique can
erform the bestMO quantification, with first-pass myocardial
erfusion (16,17) competing with gradient-echo without
1,11) and with (13,17) inversion-recovery preparatory pulse or
GE technique. The latter 2 sequences can add infarct size
nformation and have better spatial resolution, although the
atter 1 has been best validated against microspheres (1).
irst-pass perfusion can present defects owing to chronic
nfarcts, artifacts, or other flow heterogeneities. Late gadolin-
um enhancement uses an inversion-recovery preparatory pulse
hat is adjusted to null the signal of normal myocardium. The
ffect of adjusting TI time on the MO size is not well
nderstood. For instance, slight changes in TI might poten-
ially cause a rim of bright signal on the border between the
nfarct and theMO area, causing an artificial reduction inMO
ize. Moreover, these current sequences are still techniques
ependent on gadolinium dynamics.
Thus, we can still potentially benefit from even better
MR sequences not influenced by the gadolinium dynam-
cs. Some future candidates may be T2 imaging, diffusion-
eighted diffusion-tension imaging, and blood oxygenated
evel-dependent imaging.
But why should we define the anatomic area of MO so
recisely? The no-reflow area can be closely related to a
rogressive hemorrhage of the myocardium, and if it grows
ver time after reperfusion it might be considered a reperfusion
njury and, therefore, can be potentially avoided or treated. The
recise definition of MO magnitude would open an opportu-
ity to define influential factors on its course and to evaluate
urrent and new therapy effects on MO and its clinical
mplications. In the future, with these developments, we will
otentially be able to provide to acute MI patients the ultimate
yocardial reperfusion, that is, not limited to the epicardial
oronary artery, and likely an improved healing process.
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